ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
March 02 2021 - 6:30AM
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage
oncology company focused on developing treatments that address
mechanisms of therapeutic resistance, today announced that Jacob
Chacko, M.D., chief executive officer, will present a company
overview at the following investor conferences in March:
- H.C. Wainwright Global Life Sciences
Conference – On-demand pre-recorded company overview
available on March 9, 2021 at 7:00 a.m. ET / 4:00 a.m. PT; and
- Oppenheimer 31st Annual Healthcare Conference
– Presenting company overview on March 16, 2021 at 2:30 p.m. ET /
11:30 a.m. PT.
Webcasts of each presentation will be available through the
investor section of the company’s website at www.oricpharma.com.
Replays of the webcasts will be available for 90 days following the
events.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage
biopharmaceutical company dedicated to improving patients’ lives by
Overcoming Resistance In Cancer. ORIC’s lead product
candidate, ORIC-101, is a potent and selective small molecule
antagonist of the glucocorticoid receptor, which has been linked to
resistance to multiple classes of cancer therapeutics across a
variety of solid tumors. ORIC-101 is currently in two separate
Phase 1b trials in combination with (1) Abraxane (nab-paclitaxel)
in advanced or metastatic solid tumors and (2) Xtandi
(enzalutamide) in metastatic prostate cancer. ORIC’s other
product candidates include (1) ORIC-533, an orally bioavailable
small molecule inhibitor of CD73, a key node in the adenosine
pathway believed to play a central role in resistance to
chemotherapy- and immunotherapy-based treatment regimens, (2)
ORIC-944, an allosteric inhibitor of the polycomb repressive
complex 2 (PRC2) via the EED subunit, being developed for prostate
cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to
selectively target EGFR and HER2 with high potency against exon 20
insertion mutations, being developed across multiple genetically
defined cancers. Beyond these four product candidates, ORIC is also
developing multiple precision medicines targeting other hallmark
cancer resistance mechanisms. ORIC has offices in South San
Francisco and San Diego, California. For more information, please
go to www.oricpharma.com.
Investor Contact:Dominic Piscitelli, Chief
Financial
Officerdominic.piscitelli@oricpharma.cominfo@oricpharma.com
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jul 2023 to Jul 2024